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Background: Cholangiocarcinomas are rare tumors, and metastasis to the intramedullary spinal cord is also rare. To
the best of our knowledge, this is the first case of simultaneous cholangiocarcinoma and intramedullary spinal cord
metastasis to be described in the medical literature.
Case presentation: A 62-year-old Caucasian male with a cholangiocarcinoma presented pain around his left shoulder
without any other symptoms. The results by magnetic resonance imaging and F18 fluorodeoxyglucose positron
emission tomography/computer tomography revealed an intramedullary metastasis at the C4 level, with spinal
cord compression, and numerous secondary parenchymal brain metastases.
Conclusion: This patient was treated successfully with a combination of radiotherapy, corticosteroids, and
chemotherapy. He experienced complete relief of the symptoms and showed improvements upon subsequent
radiological evaluations.
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Cholangiocarcinomas are rare tumors that develop in
the bile duct. Their incidence worldwide is <1 out of
100,000 persons per year. The prognosis for patients
with cholangiocarcinoma is quite poor; the median sur-
vival for patients with unresectable cholangiocarcinoma
is <1 year. However, in 67% of patients with extrahepatic
cholangiocarcinoma, Whipple’s duodenopancreatectomy
is an option that increases the 5-year survival rate from
12% (for patients unable to receive the operation) to
28% for those that undergo the surgery [1]. Central ner-
vous system metastases of cholangiocarcinoma are ex-
tremely rare; only a few cases have been reported in the
literature. Both meningeal carcinomatosis and brain me-
tastases of cholangiocarcinoma have been described
[2-4]. To our knowledge, this study provides the first
description of a patient with cholangiocarcinoma that
presented with brain metastases and with intramedullary
spinal cord metastasis (ISCM).* Correspondence: laurence.faugeras@uclouvain.be
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Following the appearance of a rapidly evolving jaundice,
a 62-year-old Caucasian male was diagnosed with mod-
erately differentiated cholangiocarcinoma localized at
the level of the common biliary duct. This tumor was
classified as cT3N0M0, or subtype I, according to the
Bismuth classification. A surgical resection was per-
formed with Whipple’s duodenocephalic pancreatec-
tomy. Two years later, he presented with postprandial
pain, and he had lost approximately 20 kg in 1 year.
These symptoms were found to be associated with
recurrence in the liver and lung. The patient began
chemotherapy with cisplatin and gemcitabine (cisplatin
at a dose of 30 mg/m2 and gemcitabine at 1,000 mg/m2
on days 1 and 8, respectively, every 3 weeks). Given the
excellent therapeutic response after nine courses, the
patient continued monotherapy with gemcitabine alone.
Despite the stability of persistent lesions in the liver and
lymph nodes, this medication was discontinued, due to
the appearance of a discrete pulmonary infiltrate, which
suggested gemcitabine toxicity. At the 5-month follow-
up examination, the patient reported pain around his left
shoulder without any other symptoms. A computed
tomography (CT) scan showed an increase in the size of
a lung nodule. F18 fluorodeoxyglucose (FDG) positronal. This is an Open Access article distributed under the terms of the Creative
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the cholangiocarcinoma. Moreover, there were two other
suspicious lesions: one was in the anterior portion of the
vertebral body of L2 and the other was located intrame-
dullary at the C4 level (Figure 1). When the patient
returned to learn the results, he reported that, within
the last 36 h, he had developed a motor deficit in his left
arm. The pain in the upper part of the left shoulder had
also persisted. Therefore, magnetic resonance imaging
(MRI) was performed, and the results confirmed an intra-
medullary metastasis at the C4 level with spinal cord com-
pression (Figure 2). The MRI results also revealed
numerous parenchymal brain metastases (Figure 3). The
high number of brain metastases disqualified the patient
for neurosurgery. In addition, the risk of operating on the
spinal lesion was considered too high for either a complete
resection of the lesion or a decompressive cranial laminec-
tomy. The next day, radiotherapy of the whole brain and
cervical spine to C5 was started, combined with cortico-
steroid therapy (64 mg methylprednisolone/day). A total
dose of 30 Gy was administered in daily fractions of 3 Gy,
dispensed with two lateral photon beams shaped with a
multi-leaf collimator. After completion of the radiother-
apy, systemic treatment with cisplatin and gemcitabine
was reinitiated, due to the patient’s previous excellent
response to this chemotherapy regimen. The clinical evo-
lution of the symptoms rapidly became favorable in terms
of managing pain and neurological deficit. By the middle
of the radiotherapy treatment, the patient had completely
recovered from the paresis in the left upper extremity. At
the time of publication of the present study, he remained
on chemotherapy without any signs of neurological or
systemic progression.
Discussion
A careful search of the literature for brain metastasis of
cholangiocarcinoma did not reveal any cases similar to
the one described herein. Therefore, this case study wasFigure 1 F18 fluorodeoxyglucose positron emission
tomography/computed tomography shows spinal cord
intramedullary metastasis of cholangiocarcinoma at the C4
level. Metabolic activity (standardized uptake values of 6.7 g/ml)
was observed in the left paramedian intraductal region (arrow).the first to describe cholangiocarcinoma with intrame-
dullary metastasis.
The occurrence of ISCM is rare; ISCM represents
4.2–8.5% of tumors in the central nervous system and <5%
of spinal cord tumors. ISCM occurs in only 0.1–2.1% of all
patients with lung cancer [5,6]. The most common cancers
associated with this type of lesion are lung cancer (half of
the cases, particularly the small-cell subtype) [5,6], followed
by breast cancer [5-7], and infrequently, renal carcinoma,
melanoma, lymphoma, and colorectal and ovarian adeno-
carcinomas. The most common location of ISCM is cer-
vical, in 41% of cases [5,6], followed by lumbar and
thoracic, in 32–38% and 26–34% of cases, respectively [5,6].
These lesions are probably most frequently observed in the
cervical region because the cervix has large vessels, and
there is a local abundance of blood vessels [5].
When ISCMs are diagnosed, brain metastases are
found concurrently in 41–89% of cases [5-7]. Thus, it is
recommended that, when finalizing the work-up for
ISCM, clinicians should carry out a cerebral MRI to
search for metastases in the brain.
In most cases of ISCM, patients present with a history
of weakness, loss of sensitivity, or sphincter disorder.
More rarely, other symptoms, such as back pain, radicu-
lar pain, or Brown–Séquard syndrome, are encountered.
In rare cases, the finding of ISCM is fortuitous (1–8% of
patients) [5,8]. When symptoms suggestive of ISCM
occur, the diagnosis relies mainly on MRI, which
remains the gold standard; MRI detection is superior to
detection with myelography and myeloscanning. A re-
cent study by Flanagan et al. showed that 81% of neo-
plastic lesions of the spinal cord were hypermetabolic,
with an average standardized uptake value (SUV) of up
to 3.3 g/ml [9]; thus, FDG PET/CT may be helpful for
the detection and diagnosis of ISCM. Some cases of
ISCM diagnosed with FDG PET/CT were previously de-
scribed, particularly for tumors of pulmonary, renal, and
breast origins [10-13]. Although FDG PET/CT provides
less sensitivity than MRI, FDG PET/CT provides the ad-
vantage of allowing an assessment of extramedullary
disease status.
ISCM may occur via several modes of dissemination.
Three different modes have been proposed in the literature
[5,10]. The first possible mode of dissemination is through
the vascular system. The proposal of hematogenous dis-
semination was supported by the coexistence of lung and
brain metastases, which could result when metastatic
agents are transported through the vascular system [5]. A
second mechanism for ISCM is carcinomatous meningitis.
Tumor cells present in the cerebrospinal fluid (CSF) can
infiltrate the vascular Virchow–Robin spaces, enter the
spinal cord, and invade the spinal cord parenchyma [5].
The third possible mode of dissemination is transmission
by contiguity. Although the dura mater should be
Figure 2 Magnetic resonance imaging of intramedullary spinal cord metastasis of cholangiocarcinoma. (a) Magnetic resonance imaging
of the cervical spine with T2 short-tau inversion recovery sequences show intramedullary metastases of cholangiocarcinoma at the C4 level. The
hyperintensity extended in the spinal cord cranially and caudally relative to the lesion, corresponding to perilesional edema (arrow). (b) Magnetic
resonance imaging T1 sequences of the cervical spinal cord acquired at the same level as in (a). Images show contrast enhancement around the
medullary lesion, which was moderately intense in the central region and at the periphery (arrow). (c) Three months after radiotherapy, magnetic
resonance imaging T1 sequences show that the intramedullary spinal metastasis had regressed markedly.
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mater, via the extradural space of CSF or nerve roots, into
the subarachnoid space [5]. The most likely mode of dis-
semination in our patient was hematogenous, given the
simultaneous occurrence of cholangiocarcinoma and brain
metastases, even though the metastatic spread of cholan-
giocarcinoma typically occurs via the lymphatic system [2].
The classic treatment modalities for ISCM are radio-
therapy, surgery, chemotherapy, corticosteroids, or
palliative care, when the general status of the patient isFigure 3 Magnetic resonance imaging of brain metastases of cholang
observed before radiotherapy in a T1 multiplanar reconstruction of magne
gadolinium chelated contrast agent. Rounded lesions are present in the lef
enhancement and are moderately thick and irregular. The lesion center is h
corresponding to perilesional edema (thin arrow) is also present. (b) Evolut
followed by chemotherapy. The lesion volume is reduced, but no changes
perilesional edema.highly altered. Several small case series have supported
the notion that surgery provided superior treatment, in
terms of improving symptoms and overall survival [5,6].
The surgical option is preferentially adopted when a sin-
gle lesion is observed and the systemic disease is under
control, when the estimated survival is sufficiently long,
and when the general condition of the patient is good
[6]. In contrast to surgery, radiotherapy can be delivered
simultaneously to brain and/or spinal lesions. Chemo-
therapy appears to be a preferred option for highlyiocarcinoma. (a) Multiple metastases of the cholangiocarcinoma were
tic resonance imaging sequences after intravenous injection of a
t frontal lobe and right cerebellum. The lesions show peripheral
ypointense or nonenhancing (thick arrows). A perilesional hyposignal
ion of brain metastases 2 months after the end of radiotherapy,
are apparent in the enhancement features or in the
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cell lung cancer [6]. Despite the poor radiosensitivity
and chemosensitivity of cholangiocarcinoma [14,15],
whole brain and cervical radiotherapy followed by
chemotherapy with gemcitabine and cisplatin was an
effective treatment in our patient. The patient responded
quite well, and at the time of publication, he remained
asymptomatic on continuing chemotherapy.
Cholangiocarcinomas are considered to be poorly che-
mosensitive. However, this statement must be put into
perspective, because cholangiocarcinoma is a rare dis-
ease, and we lack large-scale studies. Most studies
included a limited number of patients, were not random-
ized, and were not controlled. This case report confirmed
that some patients with advanced cholangiocarcinomas
can achieve prolonged survival with chemotherapy.
However, overall survival is also determined by the
subtype of cholangiocarcinoma. Extrahepatic cholangio-
carcinomas are subclassified by phenotype as sclerosing,
nodular, or papillary. The papillary variant is most com-
monly observed in the distal bile duct, and its prognosis
is more favorable than those of the two other subtypes.
Seventy percent of hilar cholangiocarcinomas are the
sclerosing variant [16].
The prognosis of ISCM is extremely poor, with a me-
dian survival of 4 months after diagnosis. The median
survival increases to 6 months for patients treated with
surgery and to 5 months for patients treated with radio-
therapy. In patients that cannot be treated, the median
survival drops to 1 month from diagnosis [17].
The rising occurrence of cerebral and intramedullary
spine metastases of cholangiocarcinomas is probably
due to improvements in the overall survival of patients,
with the advent of multimodal therapies. In metastatic
disease, the median survival is approximately 7–12
months. Recent studies have shown prolonged overall
survival and progression-free survival with modern
management strategies for this kind of tumor, including
radiosurgery, radiation alone, and adjuvant or palliative
chemotherapy [14]. The combination of cisplatin and
gemcitabine remains the first choice for chemotherapy
in palliative situations [17].
Conclusions
Cholangiocarcinomas are rare tumors; their metastases
into the brain are even rarer. This study described a pa-
tient with cerebral metastasis of a cholangiocarcinoma
and ISCM. To our knowledge, this study was the first to
describe this type of case. The prognosis for this type of
cancer is extremely poor. However, our patient was
treated successfully with a combination of radiotherapy,
corticosteroid, and chemotherapy. He achieved complete
relief of symptoms and showed improvements upon
subsequent radiological evaluations.Consent
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